Drawing for DERAPHAN

USPTO serial 87827876

DERAPHAN

Reviewed by CopyMark Law Group

Reg. 5892113Status 710
Filing date
Status date
Registration date
Oct 22, 2019
Examiner
ADEYIGA, ADETAYO JANET
Law office
TMEG LAW OFFICE 109

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with DERAPHAN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sreenivasarao Vepachedu

Sreenivasarao Vepachedu EXCIVA GmbH1230 GEORGETOWN WAYVERNON HILLS, IL 60061UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Allergy medications; Amino acid preparations for medical purposes; Antiallergic medicines; Cardiovascular agents for medical purposes; Cardiovascular pharmaceuticals; Cardiovascular treatment preparations; Dietary and nutritional supplements; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disordersSECTION 8 - CANCELLEDJul 2, 2018

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 8, 2026C8..CANCELLED SEC. 8 (6-YR)—
Oct 22, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jun 11, 2020CORVREVIEW OF CORRESPONDENCE COMPLETE - INFORMATION MADE OF RECORD—
May 13, 2020APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Mar 8, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 8, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 8, 2020ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Mar 8, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 8, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 8, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 22, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 19, 2019SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Sep 18, 2019CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Aug 7, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Mar 5, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 5, 2019ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Mar 5, 2019RDX3NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED—
Mar 5, 2019RDX1ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED—
Mar 5, 2019RRDXACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED—
Mar 5, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 5, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 1, 2019ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Feb 25, 2019GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Feb 25, 2019GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 25, 2019CNFRSU - FINAL REFUSAL - WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 25, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 25, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 25, 2019CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 25, 2019CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 22, 2019ALIEASSIGNED TO LIE—
Feb 18, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 5, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 5, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 5, 2018CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 1, 2018SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Dec 1, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Nov 14, 2018IUAFUSE AMENDMENT FILED—
Nov 14, 2018EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Sep 18, 2018CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 18, 2018COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 18, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 18, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jul 24, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 24, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 4, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 21, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 21, 2018DOCKASSIGNED TO EXAMINER—
Apr 3, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 3, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 16, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 15, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 13, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance